Inactive Instrument

News Aimmune Therapeutics, Inc.

Equities

AIMT

US00900T1079

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Aimmune Therapeutics, Inc. to Present Positive Results from Phase 3 POSEIDON Study of PALFORZIAÂ« [Peanut (Arachis Hypogaea) Allergen Powder-dnfp] in Peanut-Allergic Children Aged 1 to 3 Years	22-11-10	CI
Allergy Partners Announces Strategic Collaboration with Aimmune Therapeutics, Inc. to Provide PALFORZIA® Directly to Patients	22-10-13	CI
Aimmune Therapeutics, Inc. Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for Up to 2 Years in the Journal of Allergy and Clinical Immunology	22-02-16	CI
Aimmune Therapeutics, Inc. Presents New PALFORZIA?	21-11-12	CI
Aimmune Therapeutics Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis	21-06-08	CI
Aimmune Therapeutics Announces New Clinical Data from A Pooled Analysis of Three Controlled Phase 3	21-02-25	CI
Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU	21-01-22	AQ
Aimmune Therapeutics : European Commission approves first treatment for peanut allergy	21-01-05	AQ
Aimmune Therapeutics : European Commission approves Aimmune's PALFORZIA as first-ever treatment for peanut allergy in the EU	20-12-22	AQ
Aimmune Therapeutics : European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU	20-12-21	BU
European Commission Approves Aimmune’S Palforzia as First-Ever Treatment for Peanut Allergy in the EU	20-12-21	CI
Nestle S A : shrugs off COVID-19 impact thanks to pet food and health nutrition	20-10-21	RE
AIMMUNE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers (form 8-K)	20-10-19	AQ
Aimmune Therapeutics, Inc. Announces Executive Changes	20-10-19	CI
Aimmune Therapeutics : Receives Positive CHMP Opinion on PALFORZIA for the Treatment of Patients with Peanut Allergy in Europe	20-10-19	AQ
Aimmune Therapeutics, Inc. Receives Positive CHMP Opinion on PALFORZIA® for the Treatment of Patients with Peanut Allergy in Europe	20-10-16	CI
Aimmune Therapeutics : Nestle Completes Acquisition of Aimmune Therapeutics	20-10-15	AQ
Aimmune Therapeutics, Inc. Appoints Andrew Oxtoby as President	20-10-14	CI
Aimmune Therapeutics, Inc. Appoints Andrew Oxtoby as CEO	20-10-14	CI
Aimmune Therapeutics : Nestle announces results of tender offer for Aimmune Therapeutics Inc.	20-10-13	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Aimmune Therapeutics, Inc.

Equities

AIMT

US00900T1079

Summary

Filters